Dr. Danilovski is Chief Scientific Officer (CSO) at Xellia Pharmaceuticals (Denmark), a specialty pharmaceutical company focused entirely on anti-infective treatments against serious and life-threatening infections. Other assignments include memberships at Board of Directors for Active Biotech (Sweden) and Pharmaero (Denmark), as well as being Member of the Scientific Selection Board of Novo Holding’s REPAIR Impact Fund.
Dr. Danilovski has participated in and led development of several novel and patented NCE and specialty pharmaceutical products with special emphasis on the anti-infective therapies. Moreover, he led the development of more than 100 different drug substances (APIs) and development of more than 200 different drug products (FDFs). He has authored more than 20 different patent families with granted patents and patent applications in various patent offices (USPTO, EPO, etc.).
Dr. Danilovski obtained his Ph.D. in Chemistry and Biochemistry from the Cambridge University in the United Kingdom and from the University of Zagreb in Croatia, and is also currently holding position of an Associate Professor at the Department of Biotechnology, University of Rijeka (Croatia).